PXR antagonists and implication in drug metabolism

References

• Anonymous. (2006). About the cover: St. John’s wort. J Soc Integr Oncol 4:52–55.
   PubMedGoogle Scholar
• Back, D. J., Orme, M. L. (1990). Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18:472–484.
   PubMed Web of Science ®Google Scholar
• Baciewicz, A. M., Chrisman, C. R., Finch, C. K., Self, T. H. (2008). Update on rifampin and rifabutin drug interactions. Am J Med Sci 335:126–136.
   PubMed Web of Science ®Google Scholar
• Barry, M., Gibbons, S., Back, D., Mulcahy, F. (1997). Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 32:194–209.
   PubMed Web of Science ®Google Scholar
• Bates, D. W. (1998). Drugs and adverse drug reactions: how worried should we be? JAMA 279:1216–1217.
   PubMed Web of Science ®Google Scholar
• Beard, K. (1992). Adverse reactions as a cause of hospital admission in the aged. Drugs Aging 2:356–367.
   PubMed Web of Science ®Google Scholar
• Bending, M. R., Skacel, P. O. (1977). Rifampicin and methadone withdrawal. Lancet 1:1211.
   PubMed Web of Science ®Google Scholar
• Benoit, G., Malewicz, M., Perlmann, T. (2004). Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Trends Cell Biol 14:369–376.
   PubMed Web of Science ®Google Scholar
• Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydow-Backman, M., et al. (1998). Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 95:12208–12213.
   PubMed Web of Science ®Google Scholar
• Biswas, A., Mani, S., Redinbo, M. R., Krasowski, M. D., Li, H., Ekins, S. (2009). Elucidating the ‘Jekyll and Hyde’ nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res 26:1807–1815.
   PubMed Web of Science ®Google Scholar
• Biswas, A., Pasquel, D., Tyagi, R. K., Mani, S. (2011). Acetylation of pregnane X receptor protein determines selective function independent of ligand activation. Biochem Biophys Res Commun 406:371–376.
   PubMed Web of Science ®Google Scholar
• Blumberg, B., Sabbagh, W., Jr., Juguilon, H., Bolado, J., Jr., van Meter, C. M., Ong, E. S., et al. (1998). SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195–3205.
   PubMed Web of Science ®Google Scholar
• Borrelli, F., Izzo, A. A. (2009). Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 11:710–727.
   PubMed Web of Science ®Google Scholar
• Burk, R. F., Hill, K. E., Hunt, R. W., Jr., Martin, A. E. (1990). Isoniazid potentiation of acetaminophen hepatotoxicity in the rat and 4-methylpyrazole inhibition of it. Res Commun Chem Pathol Pharmacol 69:115–118.
   PubMedGoogle Scholar
• Buzon, V., Carbo, L. R., Estruch, S. B., Fletterick, R. J., Estebanez-Perpina, E. (2012). A conserved surface on the ligand binding domain of nuclear receptors for allosteric control. Mol Cell Endocrinol 348:394–402.
   PubMed Web of Science ®Google Scholar
• Carnahan, V. E., Redinbo, M. R. (2005). Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab 6:357–367.
   PubMed Web of Science ®Google Scholar
• Chawla, A., Repa, J. J., Evans, R. M., Mangelsdorf, D. J. (2001). Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866–1870.
   PubMed Web of Science ®Google Scholar
• Chen, T. (2010). Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev 62:1257–1264.
   PubMed Web of Science ®Google Scholar
• Chen, Y., Nie, D. (2009). Pregnane X receptor and its potential role in drug resistance in cancer treatment. Recent Pat Anticancer Drug Discov 4:19–27.
   PubMed Web of Science ®Google Scholar
• Chen, Y., Tang, Y., Guo, C., Wang, J., Boral, D., Nie, D. (2012). Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83:1112–1126.
   PubMed Web of Science ®Google Scholar
• Chen, Y., Tang, Y., Robbins, G. T., Nie, D. (2010). Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J Pharmacol Exp Ther 334:999–1008.
   PubMed Web of Science ®Google Scholar
• Cheng, J., Krausz, K. W., Tanaka, N., Gonzalez, F. J. (2012a). Chronic exposure to rifaximin causes hepatic steatosis in pregnane x receptor-humanized mice. Toxicol Sci 129:456–468.
   PubMed Web of Science ®Google Scholar
• Cheng, J., Ma, X., Krausz, K. W., Idle, J. R., Gonzalez, F. J. (2009). Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos 37:1611–1621.
   PubMed Web of Science ®Google Scholar
• Cheng, J., Shah, Y. M., Gonzalez, F. J. (2012b). Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 33:323–330.
   PubMed Web of Science ®Google Scholar
• Cheng, J., Shah, Y. M., Ma, X., Pang, X., Tanaka, T., Kodama, T., et al. (2010). Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 335:32–41.
   PubMed Web of Science ®Google Scholar
• Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Bostrom, P., Laznik, D., et al. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466:451–456.
   PubMed Web of Science ®Google Scholar
• Choi, J. H., Banks, A. S., Kamenecka, T. M., Busby, S. A., Chalmers, M. J., Kumar, N., et al. (2011). Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477:477–481.
   PubMed Web of Science ®Google Scholar
• Crippin, J. S. (1993). Acetaminophen hepatotoxicity: potentiation by isoniazid. Am J Gastroenterol 88:590–592.
   PubMed Web of Science ®Google Scholar
• Curran, A., Ribera, E. (2011). HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin. Expert Rev Anti Infect Ther 9:1115–1118.
   PubMed Web of Science ®Google Scholar
• Das, B. C., Madhukumar, A. V., Anguiano, J., Kim, S., Sinz, M., Zvyaga, T. A., et al. (2008). Synthesis of novel ketoconazole derivatives as inhibitors of the human pregnane X receptor (PXR; NR1I2; also termed SXR, PAR). Bioorg Med Chem Lett 18:3974–3977.
   PubMed Web of Science ®Google Scholar
• de Haan, W., de Vries-van der Weij, J., Mol, I. M., Hoekstra, M., Romijn, J. A., Jukema, J. W., et al. (2009). PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice. Biochim Biophys Acta 1791:191–197.
   PubMed Web of Science ®Google Scholar
• di Masi, A., De Marinis, E., Ascenzi, P., Marino, M. (2009). Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med 30:297–343.
   PubMed Web of Science ®Google Scholar
• Dong, H., Lin, W., Wu, J., Chen, T. (2010). Flavonoids activate pregnane x receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells. BMC Biochem 11:23.
   PubMed Web of Science ®Google Scholar
• Dou, W., Mukherjee, S., Li, H., Venkatesh, M., Wang, H., Kortagere, S., et al. (2012). Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis. PLoS One 7:e36075.
   Web of Science ®Google Scholar
• Dowell, J. A., Knebel, W., Ludden, T., Stogniew, M., Krause, D., Henkel, T. (2004). Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 44:590–598.
   PubMed Web of Science ®Google Scholar
• Duret, C., Daujat-Chavanieu, M., Pascussi, J. M., Pichard-Garcia, L., Balaguer, P., Fabre, J. M., et al. (2006). Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol 70:329–339.
   PubMed Web of Science ®Google Scholar
• Dvorak, Z. (2011). Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition. Toxicol Lett 202:129–132.
   PubMed Web of Science ®Google Scholar
• Ekins, S., Chang, C., Mani, S., Krasowski, M. D., Reschly, E. J., Iyer, M., et al. (2007). Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 72:592–603.
   PubMed Web of Science ®Google Scholar
• Ekins, S., Kholodovych, V., Ai, N., Sinz, M., Gal, J., Gera, L., et al. (2008). Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 74:662–672.
   PubMed Web of Science ®Google Scholar
• Fromm, M. F., Eckhardt, K., Li, S., Schanzle, G., Hofmann, U., Mikus, G., et al. (1997). Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 72:261–267.
   PubMed Web of Science ®Google Scholar
• Fuchs, I., Hafner-Blumenstiel, V., Markert, C., Burhenne, J., Weiss, J., Haefeli, W. E., et al. (2012). Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol Sep 12. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gollamudi, R., Gupta, D., Goel, S., Mani, S. (2008). Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism. Curr Drug Metab 9:611–613.
   PubMed Web of Science ®Google Scholar
• Goodwin, B., Redinbo, M. R., Kliewer, S. A. (2002). Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 42:1–23.
   PubMed Web of Science ®Google Scholar
• Gronemeyer, H., Gustafsson, J. A., Laudet, V. (2004). Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950–964.
   PubMed Web of Science ®Google Scholar
• Grub, S., Bryson, H., Goggin, T., Ludin, E., Jorga, K. (2001). The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin, and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 57:115–121.
   PubMed Web of Science ®Google Scholar
• Guengerich, F. P. (1997). Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 43:7–35.
   PubMedGoogle Scholar
• Guo, G. L., Moffit, J. S., Nicol, C. J., Ward, J. M., Aleksunes, L. A., Slitt, A. L., et al. (2004). Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol Sci 82:374–380.
   PubMed Web of Science ®Google Scholar
• Gupta, D., Venkatesh, M., Wang, H., Kim, S., Sinz, M., Goldberg, G. L., et al. (2008). Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res 14:5332–5340.
   PubMed Web of Science ®Google Scholar
• He, J., Nishida, S., Xu, M., Makishima, M., Xie, W. (2011). PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts. Gastroenterology 140:2095–2106.
   PubMed Web of Science ®Google Scholar
• Healan-Greenberg, C., Waring, J. F., Kempf, D. J., Blomme, E. A., Tirona, R. G., Kim, RB. (2008). A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos 36:500–507.
   PubMed Web of Science ®Google Scholar
• Hernandez, J. P., Mota, L. C., Baldwin, W. S. (2009). Activation of CAR and PXR by dietary, environmental, and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation. Curr Pharmacogenomics Person Med 7:81–105.
   PubMedGoogle Scholar
• Hoekstra, M., Lammers, B., Out, R., Li, Z., Van Eck, M., Van Berkel, T. J. (2009). Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol Pharm 6:182–189.
   PubMed Web of Science ®Google Scholar
• Holmes, V. F. (1990). Rifampin-induced methadone withdrawal in AIDS. J Clin Psychopharmacol 10:443–444.
   PubMed Web of Science ®Google Scholar
• Hu, G., Xu, C., Staudinger, J. L. (2010). Pregnane X receptor is SUMOylated to repress the inflammatory response. J Pharmacol Exp Ther 335:342–350.
   PubMed Web of Science ®Google Scholar
• Hu, Z. P., Yang, X. X., Chen, X., Cao, J., Chan, E., Duan, W., et al. (2007). A mechanistic study on altered pharmacokinetics of irinotecan by St. John’s wort. Curr Drug Metab 8:157–171.
   PubMed Web of Science ®Google Scholar
• Huang, H., Wang, H., Sinz, M., Zoeckler, M., Staudinger, J., Redinbo, M. R., et al. (2007). Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268.
   PubMed Web of Science ®Google Scholar
• Jayasagar, G., Krishna Kumar, M., Chandrasekhar, K., Madhusudan Rao, Y. (2003). Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. Drug Metabol Drug Interact 19:287–295.
   PubMedGoogle Scholar
• Jonker, J. W., Liddle, C., Downes, M. (2012). FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol 130:147–158.
   PubMed Web of Science ®Google Scholar
• Kakuda, T. N., Scholler-Gyure, M., Hoetelmans, R. M. (2011). Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 50:25–39.
   PubMed Web of Science ®Google Scholar
• Kharasch, E. D., Whittington, D., Hoffer, C., Krudys, K., Craig, K., Vicini, P., et al. (2005). Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. Clin Pharmacokinet 44:731–751.
   PubMed Web of Science ®Google Scholar
• Kliewer, S. A. (2003). The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 133(Suppl 7):2444S–2447S.
   PubMed Web of Science ®Google Scholar
• Kliewer, S. A., Goodwin, B., Willson, T. M. (2002). The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687–702.
   PubMed Web of Science ®Google Scholar
• Kliewer, S. A., Lehmann, J. M., Milburn, M. V., Willson, T. M. (1999). The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res 54:345–367; discussion, 67–68.
   PubMedGoogle Scholar
• Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., et al. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73–82.
   PubMed Web of Science ®Google Scholar
• Kojima, H., Sata, F., Takeuchi, S., Sueyoshi, T., Nagai, T. (2011). Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays. Toxicology 280:77–87.
   PubMed Web of Science ®Google Scholar
• Krausova, L., Stejskalova, L., Wang, H., Vrzal, R., Dvorak, Z., Mani, S., et al. (2011). Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem Pharmacol 82:1771–1180.
   PubMed Web of Science ®Google Scholar
• Kredo, T., Mauff, K., Van der Walt, J. S., Wiesner, L., Maartens, G., Cohen, K., et al. (2011). Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 55:5616–5623.
   PubMed Web of Science ®Google Scholar
• Kreek, M. J., Garfield, J. W., Gutjahr, C. L., Giusti, L. M. (1976). Rifampin-induced methadone withdrawal. N Engl J Med 294:1104–1106.
   PubMed Web of Science ®Google Scholar
• Lau, A. J., Yang, G., Rajaraman, G., Baucom, C. C., Chang, T. K. (2010). Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J Pharmacol Exp Ther 335:771–780.
   PubMed Web of Science ®Google Scholar
• Lazarou, J., Pomeranz, B. H., Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200–1205.
   PubMed Web of Science ®Google Scholar
• Lee, W. M. (2004) Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 40:6–9.
   PubMed Web of Science ®Google Scholar
• Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., Kliewer, S. A. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023.
   PubMed Web of Science ®Google Scholar
• Lim, Y. P., Ma, C. Y., Liu, C. L., Lin, Y. H., Hu, M. L., Chen, J. J., et al. (2012). Sesamin: a naturally occurring lignan inhibits CYP3A4 by antagonizing the pregnane X receptor activation. Evid Based Complement Alternat Med 2012:242810.
   Google Scholar
• Liu, C. L., Lim, Y. P., Hu, M. L. (2012). Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 10:242–257.
   PubMed Web of Science ®Google Scholar
• Lotsch, J., Skarke, C., Tegeder, I., Geisslinger, G. (2002). Drug interactions with patient-controlled analgesia. Clin Pharmacokinet 41:31–57.
   PubMed Web of Science ®Google Scholar
• Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., et al. (1995). The nuclear receptor superfamily: the second decade. Cell 83:835–839.
   PubMed Web of Science ®Google Scholar
• Mani, S., Huang, H., Sundarababu, S., Liu, W., Kalpana, G., Smith, A. B., et al. (2005). Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res 11:6359–6369.
   PubMed Web of Science ®Google Scholar
• Masson, D., Lagrost, L., Athias, A., Gambert, P., Brimer-Cline, C., Lan, L., et al. (2005). Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler Thromb Vasc Biol 25:2164–2169.
   PubMed Web of Science ®Google Scholar
• Meyer, U. A. (1976). Drug interactions. [Article in German]. Schweiz Med Wochenschr 106:424–426.
   PubMedGoogle Scholar
• Moore, J. T., Kliewer, S. A. (2000). Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1–10.
   PubMed Web of Science ®Google Scholar
• Moore, L. B., Maglich, J. M., McKee, D. D., Wisely, B., Willson, T. M., Kliewer, S. A., et al. (2002). Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 16:977–986.
   PubMed Web of Science ®Google Scholar
• Moore, T. W., Mayne, C. G., Katzenellenbogen, J. A. (2010). Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 24:683–695.
   PubMed Web of Science ®Google Scholar
• Moreau, A., Teruel, C., Beylot, M., Albalea, V., Tamasi, V., Umbdenstock, T., et al. (2009). A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 49:2068–2079.
   PubMed Web of Science ®Google Scholar
• Moya, M., Gomez-Lechon, M. J., Castell, J. V., Jover, R. (2010). Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact 184:376–387.
   PubMed Web of Science ®Google Scholar
• Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., Kivisto, K. T. (2003). Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819–850.
   PubMed Web of Science ®Google Scholar
• Novotna, A., Doricakova, A., Vrzal, R., Maurel, P., Pavek, P., Dvorak, Z. (2010). Investigation of Orlistat effects on PXR activation and CYP3A4 expression in primary human hepatocytes and human intestinal LS174T cells. Eur J Pharm Sci 41:276–280.
   PubMed Web of Science ®Google Scholar
• Orans, J., Teotico, D. G., Redinbo, M. R. (2005). The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol Endocrinol 19:2891–2900.
   PubMed Web of Science ®Google Scholar
• Pagliaro, L., Felding, J., Audouze, K., Nielsen, S. J., Terry, R. B., Krog-Jensen, C., et al. (2004). Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 8:442–449.
   PubMed Web of Science ®Google Scholar
• Pea, F., Pavan, F., Furlanut, M. (2008). Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin Pharmacokinet 47:449–462.
   PubMed Web of Science ®Google Scholar
• Poirier, A., Funk, C., Lave, T., Noe, J. (2007). New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discov Devel 10:74–83.
   PubMed Web of Science ®Google Scholar
• Pondugula, S. R., Mani, S. (2012). Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett 328:1–9.
   PubMed Web of Science ®Google Scholar
• Poulton, E.J., Levy, L., Lampe, J.W., Shen, D.D., Tracy, J., Shuhart, M.C., Thummel, K.E., Eaton, D.L. (2012). Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. Toxicol Appl Pharmacol pii: S0041-008X(12)00471-1.
   Google Scholar
• Raynal, C., Pascussi, J. M., Leguelinel, G., Breuker, C., Kantar, J., Lallemant, B., et al. (2010). Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer 2010;9:46.
   PubMed Web of Science ®Google Scholar
• Reschly, E. J., Krasowski, M. D. (2006). Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 7:349–365.
   PubMed Web of Science ®Google Scholar
• Rosskopf, D., Kroemer, H. K., Siegmund, W. (2009). Pharmacokinetic problems in clinical practice: role of drug transporters. [Article in German]. Dtsch Med Wochenschr 134:345–356; quiz, 57–60.
   PubMed Web of Science ®Google Scholar
• Ruschitzka, F., Meier, P. J., Turina, M., Lüscher, T. F., Noll, G. (2000). Acute heart transplant rejection due to Saint John’s wort. Lancet 355:548–549.
   PubMed Web of Science ®Google Scholar
• Schafer-Korting, M. (1993). Pharmacokinetic optimisation of oral antifungal therapy. Clin Pharmacokinet 25:329–341.
   PubMed Web of Science ®Google Scholar
• Scheen, A. J. (2007). Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 46:1–12.
   PubMed Web of Science ®Google Scholar
• Shukla, S. J., Sakamuru, S., Huang, R., Moeller, T. A., Shinn, P., Vanleer, D., et al. (2011). Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos 39:151–159.
   PubMed Web of Science ®Google Scholar
• Staudinger, J. L., Xu, C., Biswas, A., Mani, S. (2011). Post-translational modification of pregnane x receptor. Pharmacol Res 64:4–10.
   PubMed Web of Science ®Google Scholar
• Sugatani, J., Uchida, T., Kurosawa, M., Yamaguchi, M., Yamazaki, Y., Ikari, A., et al. (2012). Regulation of pregnane X receptor (PXR) function and UGT1A1 gene expression by posttranslational modification of PXR protein. Drug Metab Dispos 40:2031–2040.
   PubMed Web of Science ®Google Scholar
• Sugatani, J., Yamakawa, K., Tonda, E., Nishitani, S., Yoshinari, K., Degawa, M., et al. (2004). The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 67:989–1000.
   PubMed Web of Science ®Google Scholar
• Sui, Y., Xu, J., Rios-Pilier, J., Zhou, C. (2011). Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. J Lipid Res 52:1652–1659.
   PubMed Web of Science ®Google Scholar
• Svecova, L., Vrzal, R., Burysek, L., Anzenbacherova, E., Cerveny, L., Grim, J., et al. (2008). Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos 36:339–348.
   PubMed Web of Science ®Google Scholar
• Synold, T. W., Dussault, I., Forman, B. M. (2001). The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584–590.
   PubMed Web of Science ®Google Scholar
• Takeshita, A., Taguchi, M., Koibuchi, N., Ozawa, Y. (2002). Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 277:32453–32458.
   PubMed Web of Science ®Google Scholar
• Thornton, J. W. (2001). Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci U S A 98:5671–5676.
   PubMed Web of Science ®Google Scholar
• Venkatesh, M., Wang, H., Cayer, J., Leroux, M., Salvail, D., Das, B., et al. (2011). In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol 80:124–135.
   PubMed Web of Science ®Google Scholar
• Vethe, N. T., Midtvedt, K., Asberg, A., Amundsen, R., Bergan, S. (2011). Drug interactions and immunosuppression in organ transplant recipients. [Article in Norwegian]. Tidsskr Nor Laegeforen 131:2000–2003.
   PubMedGoogle Scholar
• Wang, H., Huang, H., Li, H., Teotico, D. G., Sinz, M., Baker, S. D., et al. (2007). Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res 13:2488–2495.
   PubMed Web of Science ®Google Scholar
• Wang, H., Li, H., Moore, L. B., Johnson, M. D., Maglich, J. M, Goodwin, B., et al. (2008). The phytoestrogen coumestrol is a naturally occurring. antagonist of the human pregnane X receptor. Mol Endocrinol 22:838–857.
   PubMed Web of Science ®Google Scholar
• Wang, H., Venkatesh, M., Li, H., Goetz, R., Mukherjee, S., Biswas, A., et al. (2011). Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest 121:3220–3232.
   PubMed Web of Science ®Google Scholar
• Watkins, R. E., Davis-Searles, P. R., Lambert, M. H., Redinbo, M. R. (2003a). Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331:815–828.
   PubMed Web of Science ®Google Scholar
• Watkins, R. E., Maglich, J. M., Moore, L. B., Wisely, G. B., Noble, S. M., Davis-Searles, P. R., et al. (2003b). 2.1 A crystal structure of human PXR in complex with the St. John’s wort compound hyperforin. Biochemistry 42:1430–1438.
   PubMed Web of Science ®Google Scholar
• Watkins, R. E., Noble, S. M., Redinbo, M. R. (2002). Structural insights into the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Devel 5:150–158.
   PubMed Web of Science ®Google Scholar
• Watkins, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., Williams, S. P., et al. (2001). The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329–2333.
   PubMed Web of Science ®Google Scholar
• White, D. B., Batayneh, Z., Bachmann, K. A. (2010). A synergism model for PPARalpha and PXR agonist effects on HDL-cholesterol and apoA1. Front Biosci (Elite Ed) 2:399–410.
   PubMedGoogle Scholar
• Xue, Y., Chao, E., Zuercher, W. J., Willson, T. M., Collins, J. L., Redinbo, M. R. (2007). Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem 15:2156–2166.
   PubMed Web of Science ®Google Scholar
• Yu, C., Chai, X., Yu, L., Chen, S., Zeng, S. (2011). Identification of novel pregnane X receptor activators from traditional Chinese medicines. J Ethnopharmacol 136:137–143.
   PubMed Web of Science ®Google Scholar
• Zhang, B., Cheng, Q., Ou, Z., Lee, J. H., Xu, M., Kochhar, U., et al. (2010). Pregnane X receptor as a therapeutic target to inhibit androgen activity. Endocrinology 151:5721–5729.
   PubMed Web of Science ®Google Scholar
• Zhou, C., King, N., Chen, K. Y., Breslow, J. L. (2009). Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J Lipid Res 50:2004–2013.
   PubMed Web of Science ®Google Scholar
• Zhou, C., Poulton, E. J., Grun, F., Bammler, T. K., Blumberg, B., Thummel, K. E., et al. (2007). The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220–229.
   PubMed Web of Science ®Google Scholar
• Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., et al. (2008). Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134:556–567.
   PubMed Web of Science ®Google Scholar